logo
Plus   Neg
Share
Email

Sempra Energy Affirms FY20 Outlook, Boosts Dividend 8% - Quick Facts

While reporting financial results for the fourth quarter on Thursday, energy infrastructure company Sempra Energy (SRE) affirmed its earnings and adjusted earnings guidance for the full-year 2020, and initiated earnings outlook for the full-year 2021. The company also increased its common stock dividend by 8 percent.
For fiscal 2020, Sempra Energy continues to project earnings in a range of $12.78 to $14.26 per share, including the estimated gain on the sale of the company's South American businesses, and adjusted earnings in a range of $6.70 to $7.50 per share.

On average, 18 analysts polled by Thomson Reuters expected the company to report earnings of $7.14 per share for the year. Analysts' estimates typically exclude special items.

Looking ahead to fiscal 2021, the company now projects earnings in a range of $7.50 to $8.10 per share.

Earlier this week, Sempra Energy's board of directors approved an 8 percent increase to the company's dividend, to $4.18 per common share from $3.87 per common share, on an annualized basis.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Moderna said Tuesday that it has reached an agreement with the U.S. to initially supply 100 million doses of its experimental vaccine for COVID-19, mRNA-1273. The U.S. government has awarded up to $1.525 billion for the vaccine. Las Vegas, Nevada-based Mr. Wok Foods has recalled about 200,000 pounds of meat and poultry products for misbranding and undeclared allergens, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The recalled products may contain known allergens such as milk, wheat, soy, peanuts, or oysters. They may also contain MSG, sesame products, or sulfites. The U.S. Food and Drug Administration approved the first oral drug to treat patients two months of age and older with spinal muscular atrophy (SMA) that can be taken at home. Roche subsidiary Genentech's Evrysdi (risdiplam) is also the second FDA-approved drug to treat this rare and often fatal genetic disease affecting muscle strength and movement.
Follow RTT